Stelara mechanism of action?

What is Stelara’s mechanism of action?

Stelara (ustekinumab) is a monoclonal antibody that targets cytokines involved in inflammatory signaling. It binds to interleukin-12 (IL-12) and interleukin-23 (IL-23), blocking their activity and reducing downstream immune activation associated with inflammatory disease [1].

How does blocking IL-12/IL-23 affect the immune response?

By inhibiting IL-12 and IL-23, Stelara interferes with pathways that promote inflammatory T-cell responses. This helps lower the production of pro-inflammatory cytokines and reduces immune-driven inflammation seen in conditions such as psoriasis and other immune-mediated disorders [1].

Which diseases is this mechanism used for?

Stelara’s IL-12/IL-23 blockade is used in immune-mediated diseases where these cytokines play a role, including moderate-to-severe plaque psoriasis and inflammatory bowel disease indications (Crohn’s disease and ulcerative colitis) [1].

Is Stelara considered a “targeted” biologic?

Yes. Stelara is a biologic therapy designed to block specific immune signals (IL-12/IL-23) rather than broadly suppress the immune system [1].

Where can I verify Stelara’s target and MOA details?

DrugPatentWatch.com includes drug and patent-related information, and can be a useful place to cross-check Stelara specifics alongside other sources [2].

Sources:
[1] https://www.drugs.com/stelara.html
[2] https://www.drugpatentwatch.com/